MindBio to Raise $650,000 in Private Placement to Advance Intoxication Detection Tech
Vancouver, British Columbia — February 18, 2026 — Leads & Copy — MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) will conduct a non-brokered private placement to raise up to $650,000 to accelerate the development of its enterprise intoxication detection solution.
The biotechnology company plans to use the funds to produce proprietary hardware and edge technologies for remote deployment in the mining industry.
The company will offer up to 1,083,333 units at a price of $0.60 per unit for gross proceeds of up to $650,000. Each unit will consist of one common share of the company and one share purchase warrant. Each warrant will entitle the holder to acquire an additional share at a price of $0.80 for a period of 36 months following the closing of the offering, subject to accelerated expiry if the closing price of the shares on the Canadian Securities Exchange exceeds $1.00 for ten consecutive trading days.
MindBio is pursuing opportunities for the use of its technology in drug and alcohol intoxication detection in the mining industry. The company intends to use the net proceeds from the offering to accelerate the development and deployment of a proprietary hardware and edge technology. This will enable the remote and scalable use of MindBio’s intoxication detection solution at mining sites, for recruitment of specialized personnel, and for general working capital purposes.
In connection with the completion of the offering, the company will pay finders’ fees to eligible third parties who have introduced subscribers to the offering. All securities issued in connection with the offering will be subject to restrictions on resale for a period of four months and one day in accordance with applicable securities laws.
Completion of the offering remains subject to final board and regulatory approvals.
Subject to final board approval, the company plans to offer certain consultants and employees of the company up to 450,000 stock options, under the company’s Omnibus Incentive Plan, with each stock option exercisable at a price of $0.75 per option and valid for a period of 12 months.
MindBio is commercializing AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The AI prediction model uses over 50 million data points to predict alcohol intoxication with accuracy, just by using the human voice. The company is now collecting data that will allow its prediction tool to work on other types of intoxication for use in consumer and enterprise environments.
Source: MindBio Therapeutics Corp.
Share this story:
